ALDACTAZIDE Drug Patent Profile
✉ Email this page to a colleague
When do Aldactazide patents expire, and what generic alternatives are available?
Aldactazide is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in ALDACTAZIDE is hydrochlorothiazide; spironolactone. There are thirty-two drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; spironolactone profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ALDACTAZIDE?
- What are the global sales for ALDACTAZIDE?
- What is Average Wholesale Price for ALDACTAZIDE?
Summary for ALDACTAZIDE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 132 |
| Drug Prices: | Drug price information for ALDACTAZIDE |
| What excipients (inactive ingredients) are in ALDACTAZIDE? | ALDACTAZIDE excipients list |
| DailyMed Link: | ALDACTAZIDE at DailyMed |
Pharmacology for ALDACTAZIDE
| Drug Class | Aldosterone Antagonist Thiazide Diuretic |
| Mechanism of Action | Aldosterone Antagonists |
| Physiological Effect | Increased Diuresis |
US Patents and Regulatory Information for ALDACTAZIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | ALDACTAZIDE | hydrochlorothiazide; spironolactone | TABLET;ORAL | 012616-004 | Dec 30, 1982 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Pfizer | ALDACTAZIDE | hydrochlorothiazide; spironolactone | TABLET;ORAL | 012616-005 | Dec 30, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
